Astrana Health, Inc. (ASTH) · Sep 23, 2026 · Guidance

Astrana Health reiterates raised EBITDA outlook as AI platform story takes center stage

Guidance reaffirmed — FY2026 adjusted EBITDA $255–280M; revenue $3.8–4.1B and FCF $105–132.5M unchanged

Astrana’s September presentation details its AI-enabled value-based care platform and operating leverage, but largely confirms guidance already disclosed.

Astrana is scaling a delegated, risk-bearing healthcare platform after integrating Prospect, using its provider network, payer relationships, and AI-enabled care and administrative tools to expand value-based care across 18 markets. The September presentation adds detail to that strategy, but does not materially change the operating story already established by the second-quarter results and prior guidance.

The financial outlook is reaffirmed, not upgraded by this filing. The presentation repeats FY2026 revenue guidance of $3.8–4.1 billion, adjusted EBITDA guidance of $255–280 million, and free cash flow guidance of $105–132.5 million. 〔0〕 Those ranges were already disclosed with the second-quarter update, so the filing confirms the framework rather than creating a fresh upside surprise.

MetricQ2 2025Q2 2026 / FY2026 outlook
Revenue (quarter)$654.8M$972.5M
Adjusted EBITDA (quarter)$48.1M$68.9M
Adjusted EPS — diluted$0.55$0.80
Free cash flow, six months—$92.9M
FY2026 revenue guidance—$3.8–4.1B
FY2026 adjusted EBITDA guidance—$255–280M
FY2026 free cash flow guidance—$105–132.5M

The useful new information is strategic detail, not a new forecast. Astrana frames itself as an AI-native operating platform spanning care delivery, payer reimbursement infrastructure, and provider technology, with approximately 1.5 million value-based members, more than 20,000 providers, and 20-plus payer partners. 〔1〕 The presentation also highlights a 210-basis-point year-over-year improvement in G&A as a percentage of revenue to 5.6% in Q2 2026. 〔2〕

Execution remains the central proof point for the thesis. Management says it is on track for the high end of the $12–15 million Prospect synergy range and that medical-cost trends at both Prospect and legacy Astrana remained within expectations. That supports the integration and operating-leverage narrative, but these claims were already part of the Q2 update rather than a newly demonstrated result.

The presentation reduces uncertainty around the business model more than it changes near-term numbers. It argues that Astrana’s shift toward full-risk contracts, growing Care Enablement revenue, and expansion into markets such as Texas can compound revenue per member and margins. However, the filing remains management’s strategic presentation and does not provide a new contract win, acquisition, guidance change, or fresh quarterly result.

Bottom line: This is a detailed confirmation of Astrana’s existing growth-and-margin story, not a new catalyst. The business appears to be executing against its raised outlook, but the filing itself is largely priced-in information because the key guidance changes were already public.

What to watch next

Q3 results and updated full-year execution, early November

Original filing on SEC EDGAR

More Astrana Health, Inc. news

Astrana Health reiterates raised EBITDA outlook as AI platform story takes center stage | ASTH Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.